Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Collegium Pharma (COLL) Misses Q4 EPS by 9c
February 25, 2021 5:18 PM ESTCollegium Pharma (NASDAQ: COLL) reported Q4 EPS of $0.20, $0.09 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $76.3 million versus the consensus estimate of $77.41 million.
Our differentiated pain portfolio performed well during the fourth quarter, laying the groundwork for a strong start in the new year, said... More
